Hospital Del Mar. Radiation Oncology Department
Barcelona, 08009, Spain
NCT Number: NCT02397733
The main objective of this study i sto evaluate the impact of prophylactic cranial irradiation (PCI) with hippocampal avoidance in the neurocognitive function and quality of life of small cell lung cancer patients.
In addition, the trial assesses the potential changes in hippocampal volumetry due to cranial irradiation using magnetic resonance imaging.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Barcelona, 08009, Spain
Prophylactic cranial irradiation (PCI) has become a standard of care for selected patients with limited and extensive stage small cell lung cancer (SCLC) who have shown benefit after chemotherapy with or without thoracic radiotherapy.
Because hippocampal involvement by metastatic disease is rare, and because preclinical and clinical evidence suggests that radiation dose received by the hippocampus during whole brain radiotherapy may play a role in radiation-induced neurocognitive decline, sparing of the hippocampus during the administration of PCI should result in lower rates of memory loss.
Previous studies have demonstrated the dosimetric capabilities of intensity modulated radiation therapy (IMRT) to conformably avoid the hippocampus without detriment to the radiation dose the remaining brain receives.
The main objective of this trial is compare neurocognitive functioning following hippocampal avoidance PCI to standard PCI treatment measured by Free and Cued Selective Reminding Test (FCSRT). The FCSRT measures verbal learning and memory. The FCSRT emphasizes encoding specificity during learning and recall. One of the secondary objectives of this trial is to test the hypothesis that the lowered neurocognitive function of the patients is due to a substantial reduction in hippocampal volume in magnetic resonance imaging (MRI). Others objectives are to evaluate quality of life (QoL) and the rate of metastases in the hippocampus.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
Time frame: Change from baseline to 3 months
Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 3 months after radiation
Time frame: Change from baseline to 6,12 and 24 months
Free and Cued Selective Reminding Test (FCSRT) evaluated at baseline and 6,12 and 24 months after radiation
Time frame: Change from baseline to 3, 6,12 and 24 months
Evaluation of hippocampus brain metastases at 3, 6, 12 and 24 months after radiation
Time frame: Change from baseline to 3, 6,12 and 24 months
Evaluation of hippocampus volume at 3, 6, 12 and 24 months after radiation
Time frame: Change from baseline to 3, 6,12 and 24 months
Evaluation of adverse effects according to Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.0 at 3, 6, 12 and 24 months after radiation
Time frame: Change from baseline to 3, 6,12 and 24 months
Evaluation of Quality of Life (QoL) measured by European Organization for Research and Treatment of Cancer (EORTC) questionnaire (QLQ C-30 and QLQ BN-20)
Time frame: Up to 5 years
From the start date of PCI until the date of death from any cause, or the last follow-up date whichever came first, assessed up to 60months"
Grupo de Investigación Clínica en Oncología Radioterapia
Other
Phase III Trial Evaluating Memory Preservation of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in Small Cell LUNG Cancer (PREMER-TRIAL)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03735095
Bronchial Neoplasms, Carcinoma, Bronchogenic
Buffalo, New York, United States
View Trial DetailsNCT04902872
Adnexal Diseases, Appendiceal Neoplasms
New Haven, Connecticut, United States
View Trial DetailsNCT05329623
Bronchial Neoplasms, Carcinoma, Bronchogenic
Orlando, Florida, United States
View Trial DetailsNCT06826677
Bronchial Neoplasms, Carcinoma, Bronchogenic
Bologna, Italy
View Trial Details